- Alternative Therapies
- Blood, Heart and Circulation
- Bones and Muscles
- Brain and Nerves
- Child health
- Cosmetic Surgery
- Digestive System
- Disorders and Conditions
- Drugs Approvals and Trials
- Environmental Health
- Ear, Nose and Throat
- Eyes and Vision
- Female Reproductive
- Genetics and Birth Defects
- Geriatrics and Aging
- Immune System
- Kidneys and Urinary System
- Life style and Fitness
- Lungs and Breathing
- Male Reproductive
- Medical Breakthroughs
- Mental Health and Behavior
- Metabolic Problems
- Oral and Dental Health
- Pregnancy and Childbirth
- Public Health and Safety
- Sexual Health
- Skin, Hair and Nails
- Substance Abuse
- Surgery and Rehabilitation
Discovery in Ghent could improve screening for sudden cardiac death
Unfortunately, newspaper articles about young athletes dying suddenly on the field are not unheard of. Such reports fuel discussions about compulsory screening, for example of young footballers, for heart failure.
Research by scientists from Ghent (VIB/UGent) and Italy will benefit these screening methods. They have discovered a link between mutations in a certain gene and the heart condition Arrhythmogenic Right Ventricular Cardiomyopathy.
Arrhythmogenic Right Ventricular Cardiomyopathy or ARVC
ARVC is a hereditary heart condition in which the heart muscle (particularly the right ventricle) is partly replaced by fatty tissue and connective tissue. Cardiac arrhythmias can occur as a result of the changes in the heart muscle. Severe arrhythmias can cause dizziness or even lead to fainting or an acute cardiac arrest (= sudden death). ARVC is a progressive disease that usually presents during the teenage years.
Known mutations in desmosomal proteins
Mutations in various genes have already been linked to ARVC. These are primarily genes that are responsible for the production of proteins in the desmosomes. Desmosomes are structures in the heart that ensure that the heart muscle cells remain connected to each other. Therefore, it was assumed that defects in the desmosomes were the most important factors in developing ARVC.
Identification of new mutations
Together with Italian scientists, Jolanda van Hengel, studied patients with ARVC who did not exhibit mutations in the desmosomal genes. The scientists identified mutations in the CTNNA3 gene in these patients, which codes for the protein αT-catenin – a component of the area composita. The area composita is a structure specifically modified to the heart, where extra strong connections between cardiac muscle cells occur.
The scientists’ findings indicate that there is a link between mutations in the CTNNA3 gene and ARVC. It was demonstrated for the first time that – in addition to desmosomal genes – an area composita gene also plays a role in the development of ARVC. Future genetic screening tests for ARVC should include the CTNNA3 gene as a standard part of the test. This would increase the value of the screening.
This research was performed in the research group of Frans van Roy in the VIB Department of Molecular Biomedical Research, UGent, headed by Bart Lambrecht.
This research was funded by FWO, UGent and VIB.
Given that this research can raise many questions of patients, we would like to refer you to the email address that VIB makes available for this purpose. Anyone can submit questions concerning this and other medically oriented research to [email protected].
Relevant scientific publication
The research is published in the leading journal European Heart Journal, van Hengel et al., Mutations in the area composita protein alpha-T-catenin are associated with arrhythmogenic right ventricular cardiomyopathy.